NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Short Interest Up 1,000.6% in December

Posted by Doug Wharley on Dec 25th, 2025

NLS Pharmaceutics Ltd. (NASDAQ:NCEL – Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 41,855 shares, a growth of 1,000.6% from the November 30th total of 3,803 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 132,110 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 132,110 shares, the short-interest ratio is currently 0.3 days. Currently, 1.1% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NCEL. Weiss Ratings reissued a “sell (e+)” rating on shares of NLS Pharmaceutics in a report on Tuesday, October 14th. Wall Street Zen downgraded shares of NLS Pharmaceutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, NLS Pharmaceutics presently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on NCEL

NLS Pharmaceutics Price Performance

Shares of NLS Pharmaceutics stock traded up $0.10 during mid-day trading on Thursday, reaching $2.63. 18,863 shares of the stock traded hands, compared to its average volume of 91,505. The business has a 50-day moving average of $6.02 and a 200 day moving average of $16.43. NLS Pharmaceutics has a fifty-two week low of $2.48 and a fifty-two week high of $33.70.

About NLS Pharmaceutics

(Get Free Report)

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.